Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kairos Pharma, Ltd. ( (KAPA) ) has shared an announcement.
On September 11, 2025, Kairos Pharma announced it will host a virtual Key Opinion Leader (KOL) event on September 18, 2025, to discuss interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer. The event will feature principal investigators and aims to provide insights into the clinical benefits of ENV105, which has shown to be well-tolerated in combination with standard hormone therapy. With prostate cancer affecting millions globally, ENV105 seeks to address the unmet need for effective treatments in cases where resistance to hormone therapies develops.
The most recent analyst rating on (KAPA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd., based in Los Angeles, California, is a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics. The company aims to overcome drug resistance and immune suppression in cancer by utilizing structural biology. Its lead candidate, ENV105, targets CD105, a protein associated with resistance to cancer treatments, and is currently in Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.
Average Trading Volume: 5,159,341
Technical Sentiment Signal: Strong Buy
For an in-depth examination of KAPA stock, go to TipRanks’ Overview page.